Drug · Small Molecule

Dovitinib

CI-DRUG-00000194Explore in graph →NCIt C76199 CHEMBL522892 CIViC Phase 3

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	2	35	—	—	2011-03
Malignant Kidney Neoplasm	Phase3	Phase 3	1	2	—	—	2011-03
Malignant Bladder Neoplasm	Phase2	Phase 2	0	1	—	—	2013-03
Malignant Breast Neoplasm	Phase2	Phase 2	0	3	—

Curated evidence

Clinical evidence (13)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–13 of 13 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FGFR1 Expression1
Dovitinib + PD173074

Clinical trials

Trials with this intervention (35)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–35 of 35 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01497392	Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers	completed	Phase 1	26	Roswell Park Cancer InstituteOTHER	1	Jul 22, 2022	clinicaltrials
NCT01732107	Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression	terminated

FGFR3 Overexpression2
Dovitinib + PD173074 + Tyrosine Kinase Inhibitor SU5402Substitutes	Bladder Carcinoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID803 The effects of FGFR inhibitors (PD173074, TKI-258 and SU5402) in bladder carcinoma cell lines were related to FGFR3 (and/or FGFR1) expression. PMID 21119661 · Lamont et al., 2011 · Open in CIViC	civic
Dovitinib	Multiple Myeloma	Predictive	D	Does Not Support Sensitivity Response	2	submitted	EID12294 Multiple myeloma (MM) is a neoplastic disorder of clonal B cells characterised by uncontrolled and aberrant proliferation of plasma cells within bone marrow, monoclonal protein in the blood or urine, … (full text at CIViC) PMID 25402977 · Scheid et al., 2015 · Open in CIViC	civic

FGFR3 Overexpression2

Dovitinib + PD173074 + Tyrosine Kinase Inhibitor SU5402Substitutes

Bladder Carcinoma

Predictive

Supports Sensitivity Response

accepted

EID803

The effects of FGFR inhibitors (PD173074, TKI-258 and SU5402) in bladder carcinoma cell lines were related to FGFR3 (and/or FGFR1) expression.

PMID 21119661 · Lamont et al., 2011 · Open in CIViC

civic

Dovitinib

Multiple Myeloma

Predictive

Does Not Support Sensitivity Response

submitted

EID12294

Multiple myeloma (MM) is a neoplastic disorder of clonal B cells characterised by uncontrolled and aberrant proliferation of plasma cells within bone marrow, monoclonal protein in the blood or urine, … (full text at CIViC)

PMID 25402977 · Scheid et al., 2015 · Open in CIViC

civic

CSF1R Expression1
Dovitinib + PexidartinibCombination	GlioblastomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	4	submitted	EID8134 A comparison of tyrosine kinase inhibitors that target glioma tumour cells directly or the tumour microenvironment were tested on a PDGF-B-driven glioma genetically engineered mouse model (PDG). The C… (full text at CIViC) PMID 28759044 · Yan et al., 2017 · Open in CIViC	civic

CSF1R Expression1

Dovitinib + PexidartinibCombination

GlioblastomaCURATED_BROADER

Predictive

Supports Sensitivity Response

submitted

EID8134

A comparison of tyrosine kinase inhibitors that target glioma tumour cells directly or the tumour microenvironment were tested on a PDGF-B-driven glioma genetically engineered mouse model (PDG). The C… (full text at CIViC)

PMID 28759044 · Yan et al., 2017 · Open in CIViC

civic

FGFR4 Overexpression1
Dovitinib + FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074Substitutes	HER2-Positive Breast CarcinomaALIAS	Predictive	D	Supports Sensitivity Response	3	submitted	EID5828 ERBB2-positive breast cancer cell lines including MDA-MB-361 and MDA-MB-453 were found to display outlier expression of FGFR4. Targeting FGFR4 in FGFR4 overexpressing ERBB2-positive breast cancer samp… (full text at CIViC) PMID 24124571 · Li et al., 2013 · Open in CIViC	civic

FGFR4 Overexpression1

Dovitinib + FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074Substitutes

HER2-Positive Breast CarcinomaALIAS

Predictive

Supports Sensitivity Response

submitted

EID5828

ERBB2-positive breast cancer cell lines including MDA-MB-361 and MDA-MB-453 were found to display outlier expression of FGFR4. Targeting FGFR4 in FGFR4 overexpressing ERBB2-positive breast cancer samp… (full text at CIViC)

PMID 24124571 · Li et al., 2013 · Open in CIViC

civic

FGFR1 Amplification3
Dovitinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	2	accepted	EID3027 Clinical trial studied the efficacy of Dovitinib on 26 patients with FGFR1 amplifications. Objective response for the cohort was 11.5%, disease control rate was 50%. 11.5% of patients exhibited partia… (full text at CIViC) PMID 27315356 · Lim et al., 2016 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	2	accepted	EID1604 Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study. Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11… (full text at CIViC) PMID 23658459 · André et al., 2013 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	2	accepted	EID12478 Dovitinib, a pan-FGFR small molecular inhibitor, has shown activity in pre-clinical models against FGFR-expressing breast cancer model cell lines, as well as as in a single agent in a phase II clinica… (full text at CIViC) PMID 28183331 · Musolino et al., 2017 · Open in CIViC	civic

FGFR1 Amplification3

Dovitinib

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID3027

Clinical trial studied the efficacy of Dovitinib on 26 patients with FGFR1 amplifications. Objective response for the cohort was 11.5%, disease control rate was 50%. 11.5% of patients exhibited partia… (full text at CIViC)

PMID 27315356 · Lim et al., 2016 · Open in CIViC

civic

〃

Malignant Breast Neoplasm

Predictive

Supports Sensitivity Response

accepted

EID1604

Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study. Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11… (full text at CIViC)

PMID 23658459 · André et al., 2013 · Open in CIViC

civic

〃

Malignant Breast Neoplasm

Predictive

Supports Sensitivity Response

accepted

EID12478

Dovitinib, a pan-FGFR small molecular inhibitor, has shown activity in pre-clinical models against FGFR-expressing breast cancer model cell lines, as well as as in a single agent in a phase II clinica… (full text at CIViC)

PMID 28183331 · Musolino et al., 2017 · Open in CIViC

civic

FGF3 Amplification1
Dovitinib	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	2	accepted	EID1606 81 patients were enrolled in a clinical trial with the FGFR inhibitor dovitinib. Four of these patients had FGF3 amplifications (qPCR) and showed tumor reductions of 100%, 30.8%, 23.0%, and 7.5%, resp… (full text at CIViC) PMID 23658459 · André et al., 2013 · Open in CIViC	civic

FGF3 Amplification1

Dovitinib

Malignant Breast Neoplasm

Predictive

Supports Sensitivity Response

accepted

EID1606

81 patients were enrolled in a clinical trial with the FGFR inhibitor dovitinib. Four of these patients had FGF3 amplifications (qPCR) and showed tumor reductions of 100%, 30.8%, 23.0%, and 7.5%, resp… (full text at CIViC)

PMID 23658459 · André et al., 2013 · Open in CIViC

civic

FGFR2 Amplification1
Dovitinib	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	2	accepted	EID1605 Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study. Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11… (full text at CIViC) PMID 23658459 · André et al., 2013 · Open in CIViC	civic

FGFR2 Amplification1

Dovitinib

Malignant Breast Neoplasm

Predictive

Supports Sensitivity Response

accepted

EID1605

PMID 23658459 · André et al., 2013 · Open in CIViC

civic

KDR R1032Q1
Axitinib + Cabozantinib + Dovitinib + LenvatinibSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	accepted	EID9339 R1032Q affects the gene's universal kinase catalytic motif. The authors found that injection of mice with COLO-320 cells that harbor this mutation resulted in tumor generation, indicating that this mu… (full text at CIViC) PMID 29588308 · Toledo et al., 2018 · Open in CIViC	civic

KDR R1032Q1

Axitinib + Cabozantinib + Dovitinib + LenvatinibSubstitutes

Malignant Colorectal NeoplasmCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID9339

R1032Q affects the gene's universal kinase catalytic motif. The authors found that injection of mice with COLO-320 cells that harbor this mutation resulted in tumor generation, indicating that this mu… (full text at CIViC)

PMID 29588308 · Toledo et al., 2018 · Open in CIViC

civic

FGFR2 Mutation1
Dovitinib + FulvestrantCombination	Malignant Endometrial NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID6457 Treatment of cell lines harboring FGFR2 mutations with dovitinib 0.5 mmol/L for 72 hours resulted in a significant decrease in cell viability of AN3CA (37.80%) and MFE-296 (53.14%). Conversely, in cel… (full text at CIViC) PMID 24448819 · Eritja et al., 2014 · Open in CIViC	civic

FGFR2 Mutation1

Dovitinib + FulvestrantCombination

Malignant Endometrial NeoplasmCURATED_BROADER

Predictive

Supports Sensitivity Response

submitted

EID6457

Treatment of cell lines harboring FGFR2 mutations with dovitinib 0.5 mmol/L for 72 hours resulted in a significant decrease in cell viability of AN3CA (37.80%) and MFE-296 (53.14%). Conversely, in cel… (full text at CIViC)

PMID 24448819 · Eritja et al., 2014 · Open in CIViC

civic

FGFR3 R248C1
Dovitinib	Transitional Cell Carcinoma	Predictive	C	Supports Sensitivity Response	4	submitted	EID8319 Purpose of study was to assess the clinical and pharmacodynamic activity of dovitinib in a treatment resistant non-muscle invasive UC of the bladder. A multi-site pilot phase 2 trial was conducted. Ke… (full text at CIViC) PMID 27932416 · Hahn et al., 2017 · Open in CIViC	civic

FGFR3 R248C1

Dovitinib

Transitional Cell Carcinoma

Predictive

Supports Sensitivity Response

submitted

EID8319

Purpose of study was to assess the clinical and pharmacodynamic activity of dovitinib in a treatment resistant non-muscle invasive UC of the bladder. A multi-site pilot phase 2 trial was conducted. Ke… (full text at CIViC)

PMID 27932416 · Hahn et al., 2017 · Open in CIViC

civic